Determinants of fitness to drive in Huntington disease

Hannes Devos1, Alice Nieuwboer, Mark Tant

  • 1Department of Rehabilitation Sciences, Belgian Road Safety Institute, Brussels, Belgium. Hannes.Devos@faber.kuleuven.be

Neurology
|October 27, 2012
PubMed

Insights

Half of Huntington disease (HD) drivers fail fitness to drive (FTDr) evaluations. A clinical screening tool accurately identifies at-risk drivers, improving road safety.

Area of Science:

  • Neuroscience
  • Neurology
  • Transportation Safety

Background:

  • Huntington disease (HD) significantly impacts cognitive and motor functions.
  • Assessing fitness to drive (FTDr) in HD patients is crucial for public safety.
  • Current screening methods for HD drivers may not be sufficiently accurate.

Purpose of the Study:

  • To identify the most accurate clinical predictors of fitness to drive (FTDr) in Huntington disease (HD).
  • To develop a reliable clinical screening tool for identifying HD patients at risk of driving impairment.

Main Methods:

  • Cross-sectional study of 60 active drivers (30 HD patients, 30 controls).
  • Utilized a clinical battery including cognitive tests (UHDRS, TMT, MMSE) and a driving simulator.
  • Compared clinical predictors and neurologist appraisal against official FTDr evaluations.

Main Results:

  • HD patients performed worse than controls on all assessments.
  • 50% of HD patients failed the FTDr evaluation.
  • A model using Symbol Digit Modalities Test, Stroop, and Trail Making Test B predicted FTDr with 87% accuracy.

Conclusions:

  • Half of active drivers with HD are unfit to drive, posing a road hazard.
  • A clinical screening tool can accurately identify HD drivers at risk.
  • This tool can enhance road safety by proactively identifying impaired drivers.
Abstract

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Genetic Lingo01:11

Genetic Lingo

Overview
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...